These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 20684147

  • 1. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris.
    Fleming C, Ganslandt C, Leese GP.
    J Drugs Dermatol; 2010 Aug; 9(8):969-74. PubMed ID: 20684147
    [Abstract] [Full Text] [Related]

  • 2. Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial.
    Silver S, Tuppal R, Gupta AK, Clonier F, Olesen M, Leeder R, Taraska V.
    J Drugs Dermatol; 2013 Aug; 12(8):882-7. PubMed ID: 23986161
    [Abstract] [Full Text] [Related]

  • 3. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris.
    Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, Fleming C, Heikkilä H, Jolliffe D, Peyri J, Svensson A, Toole J, Wozel G.
    Br J Dermatol; 2006 Jun; 154(6):1155-60. PubMed ID: 16704648
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and local safety of a calcipotriol/ betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris.
    Parslew R, Traulsen J.
    Eur J Dermatol; 2005 Jun; 15(1):37-9. PubMed ID: 15701591
    [Abstract] [Full Text] [Related]

  • 7. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH.
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [Abstract] [Full Text] [Related]

  • 8. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
    Jemec GB, Ganslandt C, Ortonne JP, Poulin Y, Burden AD, de Unamuno P, Berne B, Figueiredo A, Austad J.
    J Am Acad Dermatol; 2008 Sep; 59(3):455-63. PubMed ID: 18694678
    [Abstract] [Full Text] [Related]

  • 9. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris.
    Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, Fleming C, Heikkilä H, Williams Z, Peyri Rey J, Svensson A, Toole J, Wozel G.
    Dermatology; 2006 Sep; 213(4):319-26. PubMed ID: 17135738
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial.
    White S, Vender R, Thaçi D, Haverkamp C, Naeyaert JM, Foster R, Martinez Escribano JA, Cambazard F, Bibby A.
    Am J Clin Dermatol; 2006 Sep; 7(3):177-84. PubMed ID: 16734505
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial.
    Ortonne JP, Kaufmann R, Lecha M, Goodfield M.
    Dermatology; 2004 Sep; 209(4):308-13. PubMed ID: 15539894
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.
    Eichenfield LF, Ganslandt C, Kurvits M, Schlessinger J.
    Pediatr Dermatol; 2015 Sep; 32(1):28-35. PubMed ID: 25412565
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial.
    Saraceno R, Andreassi L, Ayala F, Bongiorno MR, Giannetti A, Lisi P, Martini P, Peris K, Peserico A, Chimenti S.
    J Dermatolog Treat; 2007 Sep; 18(6):361-5. PubMed ID: 17934937
    [Abstract] [Full Text] [Related]

  • 20. The separate daily application of tacalcitol 4 µg/g ointment and budesonide 0.25 mg/g cream is more effective than the single daily application of a two compound ointment containing calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g.
    Calzavara-Pinton P, Rossi MT, Sala R, Venturini M.
    G Ital Dermatol Venereol; 2011 Aug; 146(4):295-9. PubMed ID: 21785396
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.